The global tumor ablation market size is expected to cross USD 2,459.74 million by 2030 at a CAGR of 11.81% during the forecast period 2022-2030. Tumor ablation is a minimally invasive technique that is commonly used in the treatment of tumors of the liver, kidney, bone, and lung. It is an alternative for a patient who has failed radiotherapy, chemotherapy, or non-surgical patient. Ablation is a potential first-line treatment in the case of hepatocellular carcinomas. Increasing prevalence of cancer across the globe act as the major driver in the global tumor ablation market during 2021–2030. However, side effects and complication associated with tumor ablation hinders the growth of the global tumor ablation market during the forecast period. Rising R&D activities in tumor ablation are expected to create an opportunity in the global tumor ablation market.
The NanoKnife is a unique tool used by the Department of Radiology at the University of Alabama at Birmingham to aid in tumor ablation therapy. An interventional radiologist utilizes the NanoKnife, a minimally invasive, image-guided procedure, to kill cancer cells using electricity. In order to help eliminate tumors and make it possible for doctors to treat tumors in challenging sites, thin needles are put into the skin under imaging guidance close to the patient's tumor. When treating tumors that are close to vital structures and blood vessels, the treatment spares the surrounding tissue around the tumor.
The key manufacturers have reported that market for the medical devices segment has been negatively impacted by COVID-19 and associated deferral of medical procedures in the first half of 2020. In addition, the global regulatory landscape has also been affected as the COVID-19 pandemic continues to affect the US and global economies. To meet the challenges presented by the pandemic, the US FDA and other health authorities have shifted their resources and priorities to deal with the pandemic. These pandemic-related disruptions have led to a slightly negative impact on the processing of regulatory submissions and slow agency review times necessary for the approval or clearance of new devices.
Clinical trials are used for establishing the inclusion and exclusion criteria, determining the baseline parameters, monitoring the safety of the participants, and demonstrating the efficacy of the investigational product. A group of 36 investigators conducting clinical trials for cancer at institutions around the world between March and April 2020 was surveyed by the Cancer Research Institute (CRI). According to their findings, in the US and several countries in Europe, patient enrolment in active oncology clinical trials had reduced significantly at the time of the survey. In Europe, only 14% of the institutions continued to enroll patients at the usual rate. Over 200 interventional oncology studies were suspended, and 60% of investigators reported that the pandemic had a severe impact on clinical trials.
The growing prevalence of cancer is increasing the demand for effective treatment. The number of patients suffering from various types of cancers such as lung, blood, breast, and liver is increasing worldwide. According to GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer (IARC), 19.3 million new cancer cases and about 10 million cancer deaths occurred globally in 2020. According to the National Cancer Institute, it is estimated that 1,735,350 new cases of cancer were diagnosed, and 609,640 deaths were reported in the US in 2018. Excessive smoking and consumption of alcohol and tobacco are the important factors responsible for the increasing prevalence of cancer across the world.
The pivotal U.S. trial designed to show the safety and efficacy of TechsoMed's flagship product, BioTraceIO, in providing useful visualization and quantitative insights on procedure results in liver cancer patients undergoing ultrasound-guided percutaneous ablation procedures, has successfully finished patient enrollment, the company announced today. TechsoMed is the creator of the first-of-its-kind AI Algorithm fueled tissue viability imaging technology. The BioTraceIO software system is the only one to visualize the ablated area based on common real-time ultrasound imaging, and it does so for the purpose of assisting interventional radiologists doing tumor ablation with useful operation outcomes assessment.
Although ablation is a minimally invasive technique and is generally considered safe, there are few possible side effects after ablation therapy, including abdominal pain, infection in the liver, and fever. For instance, side effects of radiofrequency ablation in the facet and sacroiliac joints include burning and/or hypersensitivity and numbness, and/or tingling over the injection site. In addition, there are also several risks associated with the radiofrequency ablation procedure, such as hyperesthesia, superficial skin infections over the injection site, heat damage to structures adjacent to the target nerve, allergic reaction to the anesthetic used to numb the skin, and more.
The key players in the market are proactively working on R&D for improving and advancing techniques for tumor ablation. For instance, in April 2021, Medtronic plc received Breakthrough Device Designation status from the US FDA for the Emprint ablation catheter kit. This is an investigational device intended to be used in conjunction with the Emprint microwave generator and Medtronic lung navigation platform to provide a minimally invasive, localized treatment of malignant lesions in the lung. It can be used together with standard care therapy when indicated. Likewise, in July 2020, Ethicon, a Johnson & Johnson Medical Devices Company, also received the US FDA Breakthrough Device Designation for transbronchial microwave ablation technology using robotic-assisted bronchoscopy.
Global Tumor Ablation Market Share, by Technology, 2020 (%)
Source: MRFR Analysis
Value Chain Analysis/Technology Analysis/Regulatory Implications
The global tumor ablation market is growing significantly due to the increasing number of players coming forward with new and advanced products. The rising demand for tumor ablation procedures coupled with the rising investments in tumor ablation procedures research is helping manufacturers of intermediate goods to access the market. The value chain analysis of the tumor ablation market comprises major components starting from the research and product development (R&D), followed by the manufacturing of the products, distribution & sales, and ends with post-sales services.
In research and product development, research on new techniques is performed to make the products better and unique. R&D is a brainstorming process and requires high knowledge and skills. The process of product development starts with conceptualization, followed by the design of the product, then the development, and at last, the testing. The R&D team works on the improvements for new techniques by introducing new techniques which should focus on the customer needs.
In the manufacturing process, the product strategies are ready and manufacturing the product starts. The manufacturing process begins with the assembling of raw materials. Manufacturing is a fast process, and which is followed by the testing of the physical characteristics of the products. The value of this segment lies in between 55 and 60% of the total value chain.
The global tumor ablation market has been divided based on technology, treatment, application, end user.
Radiofrequency ablation is one of the common methods used to treat small tumors. High energy radio waves are used to treat the volume of tissue through needle electrodes inducing coagulative necrosis to the cancer cells with marginal injury to the adjoining tissues. Radiofrequency ablation is highly preferred among patients as it is a less toxic treatment, economical, and has minimally invasive operating properties. In addition, it uses other technologies such as ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI) to escort needle electrodes into malignant tumors. The heat created through the needle kills cancerous cells surrounding the electrode.
Microwave is the naïve technology that uses microwave energy to destroy the tumor cells using a probe. The device uses a 300 MHz to 300 GHz frequency spectrum to treat the tumor-inducing cells. In addition, the scientific, industrial, and medical microwave ablation device operates at the 915-MHz or 2.45-GHz frequencies. During the tissue treatment, the oscillating microwave field increases the temperature and kinetic energy resulting in the realignment of the polar molecules. The continuous radiation of microwaves generates a large amount of heat in the surrounding tissues creating larger ablation zones in variable tissues. The microwave tumor ablation treatment uses additional technology such as a CT scan and ultrasound to spot the accurate location of the tumor.
Irreversible electroporation uses short and strong electric fields to ablate soft tissues and generate permanent and fatal nanopores in the cell membrane, further disrupting cellular homeostasis. Irreversible electroporation, also known as Nanoknife, is one of the naïve tumor ablation technologies that are minimally invasive and preferred in treating solid tumors. In addition, IRE is a non-thermal technology that terminates cancer cells without injuring the adjoining extracellular matrix. Other devices and technologies required during the IRE tumor ablation treatment include ECG, electrodes, and muscle relaxants. IRE uses 2,000-3,000 V at a rate of 240 pulses per minute to treat patients diagnosed with tumors.
Cryoablation technology terminates cancerous cells by freezing them using a thin metal probe. The probe is directed into the tumor, and cold gasses are delivered through the probe freezing the tumor, leading to the death of the tumor cells. The intracellular and extracellular ice crystals are formed due to the freezing process resulting in cellular death. In addition, the change in freezing rate and freezing temperature leads to immediate or delayed intracellular ice crystal formation. The extracellular ice crystals are formed due to slower rates of freezing. The cryoablation treatment is performed within the range of −35°C to −20°C. In cryoablation technology, the needlelike cryoprobe is used to freeze the tumor cells ceasing the growth property of the metastatic cell. Moreover, it nearly takes 25-30 minutes to perform a cryoablation procedure.
The others segment includes laser ablation and high-intensity focused ultrasound (HIFU). Laser ablation technology is used to eradicate tumors and other lesions using a laser beam. Laser ablation surgery is accurate, efficient, safe, and precise as compared to the traditional methodologies. This type of technology can carry out deep lesion or tumor treatment. Laser ablation is used to treat tumors such as brain tumors, gastrointestinal (liver and pancreas) tumors, and prostate tumors. Moreover, HIFU is utilized to treat prostate cancer.
On the basis of the treatment, the market is divided into surgical ablation, percutaneous ablation laparoscopic ablation
Surgical ablation is the removal or destruction of tissue or a body part through surgical procedures. A wide range of tumors is treated through surgical approaches, including renal tumor, hepatic tumor, and malignant liver tumor. This treatment uses a minimally invasive approach to destroy tumor cells by burning and freezing them. The treatment is carried out for the patients having tumor cells covering an area of about 3 cm. In addition, the procedure is executed through a needle or a probe that is directed by magnetic resonance imaging, computed tomography, or ultrasound. Surgical ablation treatment cures tumors related to the liver, lung, bone, and kidney.
Percutaneous ablation uses radiofrequency to generate radio waves terminating the tumor from the operating region. The procedure is used to treat tumors related to the liver, renal, and bone. The probe is directed to the tumor site through computer-assisted tomography or ultrasound. The radio waves created around the probe destroy the surrounding tumor cells. Percutaneous ablation is highly preferred in countries such as Japan and the US. In addition, it is gaining popularity in treating inoperable primary liver tumors such as hepatocellular carcinoma (HCC).
Laparoscopic ablation is a procedure that is performed in the pelvis or the abdomen region through small incisions and camera assistance. This procedure is used to treat both primary and secondary metastatic neoplasms. Moreover, laparoscopy treatment is frequently used to treat patients with benign tumors and advanced malignancy. In addition, such types of treatments are used to treat kidney and uterus tumors.
On the basis of the application, the market is divided into liver cancer, lung cancer, kidney cancer, and others
Abnormal and fast cell differentiation in the lungs causes lung cancer. Lung cancer is the second most common cancer throughout the globe. It is further categorized into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). According to the American Cancer Society (ACS), NSCLC accounts for 80 to 85% of lung cancer cases across the globe, while SCLC accounts for 10 to 15% of lung cancer cases. NSCLC constitutes 9 of 10 lung cancer cases, and the slow spread property of cancer makes it more lethal as it cannot be traced during growth. According to the American Cancer Society, the US. is expected to diagnose 235,760 new cases of lung cancer by the end of 2021. The association also estimated the total number of deaths caused by lung cancer to be 131,880 by the end of 2021. Additionally, the maximum number of lung cancer cases constitute a population above 65 years of age, and a small number of populations under 45 years of age are diagnosed with lung cancer.
Kidney cancer is caused due to the unregulated division of cells in kidneys. It can be categorized into renal cell carcinoma, urothelial carcinoma, sarcoma, Wilms tumor, and lymphoma. Among these, renal cell carcinoma accounts for up to 85% of the diagnoses, followed by urothelial carcinoma, which records 5% to 10% of the total patients with kidney cancer. According to the American Cancer Society, in 2021, the number of kidney cancer patients is estimated to be 76,080, and the number of deaths is estimated to reach 13,780 in the US. From 2008 to 2017, the disease rate increased by 1% and was diagnosed among the population aged between 65 and 74.
Abnormal growth of cells in the liver cause liver cancer. Liver cancer can be further categorized into primary liver cancer (hepatocellular carcinoma) and secondary liver cancer (metastatic liver cancer). Primary liver cancer originates in the liver tissue, while secondary liver cancer originates in other parts of the liver and moves to the liver. In accordance with the American Cancer Society, more than 800,000 individuals are diagnosed with liver cancer across the globe whereas, this disease causes more than 700,000 demises each year.
The others segment consists of bone metastasis, breast cancer, and prostate cancer. Bone metastasis is caused when tumor cells move from the site of origination to a bone. All types of cancer can cause tumors in the bone. Breast cancer is rapidly increasing across the globe and is caused when breast cells grow in an uncontrolled manner. It is categorized into in situ and invasive breast cancers. In situ breast cancer originates in the milk duct and does not migrate to the other parts of breast tissue, whereas invasive breast cancer invades the surrounding breast tissues causing a tumor
Clinical Laserthermia Systems AB's subsidiary CLS Americas has announced it will showcase its TRANBERGTM Thermal Therapy System. In order to offer precise, targeted, and precise tumor ablation while protecting the healthy surrounding tissue, the TRANBERGTM System is built to work with a variety of MR/US fusion image guidance systems. In clinical studies, doctors in the US and EU are treating patients with low- to intermediate-risk prostate cancer using the TRANBERG system. High levels of exactness with little chance of adverse effects like erectile dysfunction and urine incontinence have been shown for focal laser ablation.
Global Tumor Ablation Market Share, by Region, 2020 (%)
Source: MRFR Analysis
The global tumor ablation market, based on region, has been divided into North America, Europe, Asia-Pacific, Rest of the World.
North America accounted for the largest market share of about 40.29% in 2020, owing to the advances in percutaneous ablation, growing demand for radiofrequency ablation for hepatocellular carcinoma, increasing geriatric population, and growing tumor-related issues among the population aged 65 years and above. According to the National Cancer Institute, in 2020, the US constitutes 1,806,590 new cases of cancer, and the country also recorded a total death of 606,520 cancer patients. However, the advancement in tumor treating techniques has increased the ratio of cancer survivors. According to the American Cancer Society, Inc., the total number of US-based male cancer survivors in 2019 was 8,138,790, whereas the number of US-based female cancer survivors was accounted to be 8,781,580. In addition, the organization had also estimated the number of male and female cancer survivors to rise by 2030.
Europe is the second-largest market for tumor ablation due to the emergence of standardized methods and tools for tumor ablation treatment, growing demand for surgery radiotherapy and chemotherapy for early detected tumors, and increasing cases of various cancer among mid-aged and geriatric population and rising consumption of unhealthy and carcinogenic products. In addition, the government authorities have introduced early detection guidelines, screening programs, and vaccination coverage to increase the survival rate of the patients. Among the different types of cancers, lung cancer has the highest mortality rate, followed by colorectal cancer. Other factors that support the increasing demand for tumor ablation treatment include infections, obesity, occupational risk, and high exposure to UV. Moreover, according to WHO, Europe contributes about one-quarter of global cancer patients with 3.7 million new patients per year. Additionally, the region records 1.9 million deaths due to cancer every year. According to the American Cancer Society, Inc., one out of every three individuals in Europe is diagnosed with cancer by the age of 75. Hungary has the largest number of male and female cancer-affected patients, followed by Ireland, Latvia, Slovakia, and the Czech Republic. Moreover, according to Globocan, the total number of new cases of cancer was recorded to be 4,398,443, and the number of cancer deaths was recorded to be 1,955,231.
Asia-Pacific is expected to grow significantly in the tumor ablation market owing to the increasing consumption of carcinogenic products such as alcohol and betel nut, limited intake of fruits and vegetables, a revelation to indoor and outdoor air pollution, and rise in exposure to chemical pollutants across the region. Countries such as China are practicing microwave technology to treat lung tumors. Patients across the region suffering from non-small cell lung cancer (NSCLC) are being treated using microwave ablation technology. Additionally, public, and private organizations are investing in the advancement of microwave ablation techniques. Moreover, Australian healthcare facilities are practicing radiofrequency and microwave ablation technologies to treat different types of cancer.
Rest of the World:
The Rest of the World is expected to witness a rise in tumor ablation treatment. The increasing use of tobacco products and the high prevalence of smoking across the Middle East and North Africa (MENA) region activate oncogenes, further developing different types of tumors. Increasing tests for tumor molecular characterization of lung cancer across the region is expected to drive the tumor ablation market. The rising number of hepatic tumors among the Rest of the World population is generating opportunities for the industry players. Moreover, the healthcare centers in Latin America are practicing different techniques to treat patients suffering from various tumors. In addition, the high consumption of tobacco-based products across the territory is the major reason for tumor formation. According to the WHO, Jordan contributes 46.9% of men with smoking habits, followed by Oman, which contributes 14.7% of men. Moreover, Latin America and Caribbean countries are experiencing a rise in the number of prostate, breast, and colorectal cases. According to Globocan, Latin America and the Caribbean recorded 1,470,274 new cancer cases and accounted for 713,414 deaths across the region.
The FDA has approved Stryker's OptaBlate bone tumor ablation technology under 510(k) clearance. Stryker, based in Michigan, created the OptaBlate technology so that doctors could quickly tailor their interventions. The system contributes to a three-minute reduction in ablation time. The system includes Stryker's unique microinfusion technology and four probes. According to the business, including it in its interventional spine portfolio will increase its capabilities in radiofrequency ablation and vertebral augmentation. According to Stryker, it completes its line of available therapies for metastatic vertebral body fractures. Additionally, OptaBlate provides a bipedicular method that enables simultaneous therapy of two vertebral body levels. It offers a speedier, more reliable ablation. According to Stryker, the microinfusion technology maintains moisture in the area. Impedance mistakes are decreased, and charring is avoided.
The key players operating in the global tumor ablation include SonaCare Medical, LLC (US), Medtronic plc (Ireland), EDAP TMS (France), Angio Dynamics (US), HealthTronics, Inc (US), Johnson & Johnson (US), Boston Scientific Corporation (US), Misonix Inc (US), HistoSonics, Inc (US), Biotronik (Germany). The rising R&D activities provide growth opportunities for the market in the future. However, side effects and complications associated with tumor ablation hamper the market's growth in the forecast period
List of Key Companies Covered in this report:
The study covers the existing short-term and long-term market effects, helping decision-makers draft short-term and long-term plans for businesses by region. The report covers major regions in North America, Europe, Asia-Pacific, Rest of the World. The report analyzes market drivers, restraints, opportunities, challenges, Porter's Five Forces, Value Chain, and impact of COVID-19 on the market.
Scope of the Report & Segmentation
Global Tumor Ablation Market, by Technology
Global Tumor Ablation Market, by Treatment
Global Tumor Ablation Market, by Application
Global Tumor Ablation Market, by End User
Global Tumor Ablation Market, by Region
|Market Size||2030: USD 2,459.74 Million|
|Historical Data||2018 & 2019|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Technology, Treatment, Application, End User, and Region|
|Geographies Covered||North America, Europe, Asia-Pacific, Rest of the World|
|Key Vendors||SonaCare Medical, LLC (US) Medtronic plc (Ireland) EDAP TMS (France) Angio Dynamics (US) HealthTronics, Inc (US) Johnson & Johnson (US) Boston Scientific Corporation (US) Misonix Inc (US) HistoSonics, Inc (US) Biotronik (Germany)|
|Key Market Opportunities||• Rising R&D activities|
|Key Market Drivers||• Rising demand for minimally invasive tumor ablation techniques • Increasing prevalence of cancer across the globe.|
The tumor ablation market had a valuation of USD 2,459.74 million in 2030.
The tumor ablation market had a predicted CAGR of 11.81% during the forecast period of 2020 to 2030.
The global tumor ablation market growth can be dampened by strict regulations and cost suppression measures.
The tumor ablation market has end users like a hospital, research institute, and surgical & ablation centers.
The Americas is leading the tumor ablation market.